KR20120093229A - 항 항체 반응을 감소시키기 위한 방법, 조성물 및 키트 - Google Patents

항 항체 반응을 감소시키기 위한 방법, 조성물 및 키트 Download PDF

Info

Publication number
KR20120093229A
KR20120093229A KR1020127010414A KR20127010414A KR20120093229A KR 20120093229 A KR20120093229 A KR 20120093229A KR 1020127010414 A KR1020127010414 A KR 1020127010414A KR 20127010414 A KR20127010414 A KR 20127010414A KR 20120093229 A KR20120093229 A KR 20120093229A
Authority
KR
South Korea
Prior art keywords
allotype
subject
phenotype
monoclonal antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127010414A
Other languages
English (en)
Korean (ko)
Inventor
죤 시마드
Original Assignee
엑스바이오테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스바이오테크, 인크. filed Critical 엑스바이오테크, 인크.
Publication of KR20120093229A publication Critical patent/KR20120093229A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020127010414A 2009-09-24 2010-09-23 항 항체 반응을 감소시키기 위한 방법, 조성물 및 키트 Ceased KR20120093229A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24530509P 2009-09-24 2009-09-24
US61/245,305 2009-09-24

Publications (1)

Publication Number Publication Date
KR20120093229A true KR20120093229A (ko) 2012-08-22

Family

ID=43756813

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127010414A Ceased KR20120093229A (ko) 2009-09-24 2010-09-23 항 항체 반응을 감소시키기 위한 방법, 조성물 및 키트

Country Status (8)

Country Link
US (6) US20110071054A1 (https=)
EP (1) EP2480252A4 (https=)
JP (1) JP2013505938A (https=)
KR (1) KR20120093229A (https=)
CN (1) CN102573895A (https=)
AU (1) AU2010298264B2 (https=)
CA (1) CA2775291A1 (https=)
WO (1) WO2011038069A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) * 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP2013505938A (ja) * 2009-09-24 2013-02-21 エックスバイオテク，インコーポレイテッド 抗抗体応答を軽減する方法、組成物およびキット
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP2014523884A (ja) * 2011-06-24 2014-09-18 セントローズ， エルエルシー 細胞外標的化薬物複合体
US20130089496A1 (en) * 2011-10-07 2013-04-11 Musc Foundation For Research Development Tumor targeted antibodies and method for using the same
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5856095A (en) * 1995-08-14 1999-01-05 St. Jude Children's Research Hospital Identification of two novel mutant alleles of human thiopurine S-methyltransferase, and diagnostic uses thereof
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
GB9925490D0 (en) * 1999-10-28 1999-12-29 Univ Cambridge Tech Binding molecules and treatment and screening methods
US20020127625A1 (en) * 2000-03-31 2002-09-12 Forskarpatent Is Syd Ab Methods of diagnosing immune related diseases
EP2288733A4 (en) * 2008-03-18 2012-03-21 Merck Sharp & Dohme PROTEIN CHANGE TEST WITH HIGH THROUGHPUT
JP2013505938A (ja) * 2009-09-24 2013-02-21 エックスバイオテク，インコーポレイテッド 抗抗体応答を軽減する方法、組成物およびキット

Also Published As

Publication number Publication date
JP2013505938A (ja) 2013-02-21
US20120094395A1 (en) 2012-04-19
EP2480252A4 (en) 2014-04-30
AU2010298264B2 (en) 2014-10-23
US20120094301A1 (en) 2012-04-19
CA2775291A1 (en) 2011-03-31
US20110071054A1 (en) 2011-03-24
WO2011038069A1 (en) 2011-03-31
US20110070230A1 (en) 2011-03-24
EP2480252A1 (en) 2012-08-01
US20110071276A1 (en) 2011-03-24
AU2010298264A1 (en) 2012-04-19
CN102573895A (zh) 2012-07-11
US20110070229A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
AU2010298264B2 (en) Methods, compositions, and kits for reducing anti-antibody responses
Siddiqui Monoclonal antibodies as diagnostics; an appraisal
EP2703485B1 (en) Method for selecting plasma cells and plasmablasts, and method for producing target antigen-specific antibody
JP2009515827A (ja) 治療薬
Barrett et al. Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype
CN116178529B (zh) 一株人源中和抗体或其抗原结合片段及其应用
Reyes et al. Broadly inhibitory antibodies against severe malaria virulence proteins
CN117866081A (zh) 一种抗新型冠状病毒的全人源单克隆抗体及其用途
US20190219577A1 (en) Membrane markers
CN117069840B (zh) 特异性检测il-21的抗体及应用
CN110655572B (zh) 一种抗丝状病毒gp蛋白的单克隆抗体及其应用
CN118546246A (zh) 特异性结合il-8的抗体、抗体片段及其用途
CN113667015B (zh) 靶向psgl-1蛋白的抗体及其用途
US12188935B2 (en) Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
US20210199667A1 (en) Analysis of soluble tlr7 in human-derived sample
CN117106077B (zh) 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN117510636B (zh) Gprc5d抗体及其应用
US20260009795A1 (en) Lymphocyte selection method
US20210405026A1 (en) Method for evaluating the presence of a viral reservoir, and evaluating the efficacy of a drug against said reservoir
JP4310499B2 (ja) 活性化リンパ球を同種補体を介して溶解させるヒトＩｇＭ抗体
Marchioni et al. Synergistic non-neutralizing plasma antibodies to PfRH5 drive potent malaria parasite growth inhibition
CN121758610A (zh) Tau蛋白289磷酸化位点特异性结合蛋白、阿尔兹海默症诊断试剂盒及其制备方法与应用
WO2025230843A2 (en) Kir binding antibodies and antigen binding fragments thereof
CN120757640A (zh) 一种球虫卵囊蛋白的单克隆抗体的制备方法
WO2023025031A1 (zh) 用于疫苗或中和抗体测试中的SARS-CoV-2病毒S蛋白中和表位

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120423

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150922

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170124

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170512

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170124

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20170901

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170124

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20170901

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170809

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170322

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20150922